# Alpha-9 Oncology

> Clinical-stage radiopharmaceutical company developing targeted cancer therapies.

## Why it is interesting

Systematic radiopharma design engine across validated and novel oncology targets — oversubscribed Series C at scale.

## Profile

- **Stage:** growth
- **Status:** private
- **Industries:** biotech-life-sciences, healthtech
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Series C (2024): $175M led by Lightspeed and Ascenta with a16z Bio + Health, General Catalyst (company press)
- Clinical-stage radiopharmaceutical platform targeting multiple oncology indications via systematic ligand design
- Co-investors not in VCT directory: Ascenta Capital

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz
- https://venturecapitaltracker.com/fund/general-catalyst
- https://venturecapitaltracker.com/fund/lightspeed-venture-partners-nyc

## Related articles

- https://venturecapitaltracker.com/2026-a16z-hot-portfolio-companies

---
Source: https://venturecapitaltracker.com/startup/alpha-9-oncology